Cargando…

A Cohort Study to Examine the Use of Chinese Herbal Medicine in Combination With Conventional Therapies for Patients With Hepatocellular Carcinoma in China

Background. Hepatocellular carcinoma (HCC) is one of the major malignancies associated with high mortality rates. Chinese herbal medicine (CHM) alone, or in combination with conventional therapies (CT), has been widely used for patients with HCC in China. This study aims to explore how integrative t...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Lingling, Fahey, Paul, Zhu, Xiaoshu, Ng, Weng, Chen, Zhuo Ping, Qiu, Yiwen, Lai, Hezheng, Lin, Jietao, Lin, Lizhu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142107/
https://www.ncbi.nlm.nih.gov/pubmed/29775121
http://dx.doi.org/10.1177/1534735418775819
_version_ 1783355808278380544
author Sun, Lingling
Fahey, Paul
Zhu, Xiaoshu
Ng, Weng
Chen, Zhuo Ping
Qiu, Yiwen
Lai, Hezheng
Lin, Jietao
Lin, Lizhu
author_facet Sun, Lingling
Fahey, Paul
Zhu, Xiaoshu
Ng, Weng
Chen, Zhuo Ping
Qiu, Yiwen
Lai, Hezheng
Lin, Jietao
Lin, Lizhu
author_sort Sun, Lingling
collection PubMed
description Background. Hepatocellular carcinoma (HCC) is one of the major malignancies associated with high mortality rates. Chinese herbal medicine (CHM) alone, or in combination with conventional therapies (CT), has been widely used for patients with HCC in China. This study aims to explore how integrative therapy (IT) through the combination of CHM and CT affects the survival of patients with intermediate-advanced HCC. Methods. A retrospective cohort study was performed at the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China. Data of consecutive patients diagnosed with intermediate-advanced HCC and a specific traditional Chinese medicine diagnostic pattern between January 2006 and December 2013 were retrieved from the electronic medical record system at the hospital. Patients were divided into 3 groups based on the therapies used, that is, IT, CHM alone, and CT alone, and the survival times of these patients was compared. Results. A total of 328 patients were included in this study. Median follow-up period was 26.4 months (95% confidence interval [CI] = 22.7-38.9). Median overall survival was 11.0 months for IT, 8.6 months for CHM, and 9.4 months for CT groups (P < .001). The adjusted hazard ratio (HR) of death for the IT group was 0.55 (95% CI = 0.38-0.79, P = .001) relative to the CT group and 0.68 (95% CI = 0.52-0.90, P = .007) relative to the CHM group, after adjusting for the factors that impact prognosis. Stratified analysis shows that IT can significantly lower the risk of death, especially for patients with good performance status (PS) and Child-Pugh class A. Conclusions. It was indicated that the integrative approach with combination of CHM and CT might improve survival for patients with intermediate-advanced HCC, especially for patients with good PS and Child-Pugh class A. However, a randomized controlled trial is warranted for a conclusive statement.
format Online
Article
Text
id pubmed-6142107
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-61421072018-09-20 A Cohort Study to Examine the Use of Chinese Herbal Medicine in Combination With Conventional Therapies for Patients With Hepatocellular Carcinoma in China Sun, Lingling Fahey, Paul Zhu, Xiaoshu Ng, Weng Chen, Zhuo Ping Qiu, Yiwen Lai, Hezheng Lin, Jietao Lin, Lizhu Integr Cancer Ther Research Articles Background. Hepatocellular carcinoma (HCC) is one of the major malignancies associated with high mortality rates. Chinese herbal medicine (CHM) alone, or in combination with conventional therapies (CT), has been widely used for patients with HCC in China. This study aims to explore how integrative therapy (IT) through the combination of CHM and CT affects the survival of patients with intermediate-advanced HCC. Methods. A retrospective cohort study was performed at the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China. Data of consecutive patients diagnosed with intermediate-advanced HCC and a specific traditional Chinese medicine diagnostic pattern between January 2006 and December 2013 were retrieved from the electronic medical record system at the hospital. Patients were divided into 3 groups based on the therapies used, that is, IT, CHM alone, and CT alone, and the survival times of these patients was compared. Results. A total of 328 patients were included in this study. Median follow-up period was 26.4 months (95% confidence interval [CI] = 22.7-38.9). Median overall survival was 11.0 months for IT, 8.6 months for CHM, and 9.4 months for CT groups (P < .001). The adjusted hazard ratio (HR) of death for the IT group was 0.55 (95% CI = 0.38-0.79, P = .001) relative to the CT group and 0.68 (95% CI = 0.52-0.90, P = .007) relative to the CHM group, after adjusting for the factors that impact prognosis. Stratified analysis shows that IT can significantly lower the risk of death, especially for patients with good performance status (PS) and Child-Pugh class A. Conclusions. It was indicated that the integrative approach with combination of CHM and CT might improve survival for patients with intermediate-advanced HCC, especially for patients with good PS and Child-Pugh class A. However, a randomized controlled trial is warranted for a conclusive statement. SAGE Publications 2018-05-18 /pmc/articles/PMC6142107/ /pubmed/29775121 http://dx.doi.org/10.1177/1534735418775819 Text en © The Author(s) 2018 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Research Articles
Sun, Lingling
Fahey, Paul
Zhu, Xiaoshu
Ng, Weng
Chen, Zhuo Ping
Qiu, Yiwen
Lai, Hezheng
Lin, Jietao
Lin, Lizhu
A Cohort Study to Examine the Use of Chinese Herbal Medicine in Combination With Conventional Therapies for Patients With Hepatocellular Carcinoma in China
title A Cohort Study to Examine the Use of Chinese Herbal Medicine in Combination With Conventional Therapies for Patients With Hepatocellular Carcinoma in China
title_full A Cohort Study to Examine the Use of Chinese Herbal Medicine in Combination With Conventional Therapies for Patients With Hepatocellular Carcinoma in China
title_fullStr A Cohort Study to Examine the Use of Chinese Herbal Medicine in Combination With Conventional Therapies for Patients With Hepatocellular Carcinoma in China
title_full_unstemmed A Cohort Study to Examine the Use of Chinese Herbal Medicine in Combination With Conventional Therapies for Patients With Hepatocellular Carcinoma in China
title_short A Cohort Study to Examine the Use of Chinese Herbal Medicine in Combination With Conventional Therapies for Patients With Hepatocellular Carcinoma in China
title_sort cohort study to examine the use of chinese herbal medicine in combination with conventional therapies for patients with hepatocellular carcinoma in china
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142107/
https://www.ncbi.nlm.nih.gov/pubmed/29775121
http://dx.doi.org/10.1177/1534735418775819
work_keys_str_mv AT sunlingling acohortstudytoexaminetheuseofchineseherbalmedicineincombinationwithconventionaltherapiesforpatientswithhepatocellularcarcinomainchina
AT faheypaul acohortstudytoexaminetheuseofchineseherbalmedicineincombinationwithconventionaltherapiesforpatientswithhepatocellularcarcinomainchina
AT zhuxiaoshu acohortstudytoexaminetheuseofchineseherbalmedicineincombinationwithconventionaltherapiesforpatientswithhepatocellularcarcinomainchina
AT ngweng acohortstudytoexaminetheuseofchineseherbalmedicineincombinationwithconventionaltherapiesforpatientswithhepatocellularcarcinomainchina
AT chenzhuoping acohortstudytoexaminetheuseofchineseherbalmedicineincombinationwithconventionaltherapiesforpatientswithhepatocellularcarcinomainchina
AT qiuyiwen acohortstudytoexaminetheuseofchineseherbalmedicineincombinationwithconventionaltherapiesforpatientswithhepatocellularcarcinomainchina
AT laihezheng acohortstudytoexaminetheuseofchineseherbalmedicineincombinationwithconventionaltherapiesforpatientswithhepatocellularcarcinomainchina
AT linjietao acohortstudytoexaminetheuseofchineseherbalmedicineincombinationwithconventionaltherapiesforpatientswithhepatocellularcarcinomainchina
AT linlizhu acohortstudytoexaminetheuseofchineseherbalmedicineincombinationwithconventionaltherapiesforpatientswithhepatocellularcarcinomainchina
AT sunlingling cohortstudytoexaminetheuseofchineseherbalmedicineincombinationwithconventionaltherapiesforpatientswithhepatocellularcarcinomainchina
AT faheypaul cohortstudytoexaminetheuseofchineseherbalmedicineincombinationwithconventionaltherapiesforpatientswithhepatocellularcarcinomainchina
AT zhuxiaoshu cohortstudytoexaminetheuseofchineseherbalmedicineincombinationwithconventionaltherapiesforpatientswithhepatocellularcarcinomainchina
AT ngweng cohortstudytoexaminetheuseofchineseherbalmedicineincombinationwithconventionaltherapiesforpatientswithhepatocellularcarcinomainchina
AT chenzhuoping cohortstudytoexaminetheuseofchineseherbalmedicineincombinationwithconventionaltherapiesforpatientswithhepatocellularcarcinomainchina
AT qiuyiwen cohortstudytoexaminetheuseofchineseherbalmedicineincombinationwithconventionaltherapiesforpatientswithhepatocellularcarcinomainchina
AT laihezheng cohortstudytoexaminetheuseofchineseherbalmedicineincombinationwithconventionaltherapiesforpatientswithhepatocellularcarcinomainchina
AT linjietao cohortstudytoexaminetheuseofchineseherbalmedicineincombinationwithconventionaltherapiesforpatientswithhepatocellularcarcinomainchina
AT linlizhu cohortstudytoexaminetheuseofchineseherbalmedicineincombinationwithconventionaltherapiesforpatientswithhepatocellularcarcinomainchina